By
Latest Stories
Don’t miss our hot and upcoming stories
AI-Powered Insilico Medicine Doses First Patient in Phase I Trial for ISM6331, Pan-TEAD Inhibitor, Targeting Mesothelioma and Solid Tumors
Cambridge, Mass. — Jan 22, 2025 Insilico Medicine, a biotechnology company leveraging generative artificial intelligence…
Insilico Medicine’s AI Platform Unveils GBP2 and HCK as Promising Targets for Endometriosis Treatment
InSilico Medicine — Jan 15, 2025AI-Driven Research Unveils New Therapeutic Approaches Researchers have leveraged artificial…
Can Yseop and Novartis Cut Drug Development Timelines by 6 Months Using Generative AI?
Elite AI Partnership with NovartisYseop has been named among only seven elite AI partners by…
Dyno Therapeutics Reveals Roche’s Decision to Exercise Option for Advanced AAV Gene Therapy in Neurological Disorders
January 13, 2025 Dyno Therapeutics has announced that Roche has exercised its option to license…